STOCK TITAN
  1. Home
  2. News
  3. CLLS

Cellectis S.A. American Depositary Shares - CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.

Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.

Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.

Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.

Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.

For more information, visit the company's website at www.cellectis.com.

News

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Rhea-AI Summary
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurological diseases, allowing for lineage-specific expression of therapeutics and efficient gene insertion without compromising cell viability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Rhea-AI Summary
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Rhea-AI Summary
Cellectis, a biotechnology company, announced the presentation of preliminary data on a novel TALEN® gene-editing process for hematopoietic stem cells at the ASGCT 27th Annual Meeting. The company showcased improvements in gene correction and insertion in HSPCs, along with a strategy for lineage-specific expression of therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
News

Monthly information on share capital and company voting rights

Rhea-AI Summary
Cellectis announces voting rights for March 2024 with a total of 77,889,229 voting rights from 71,953,535 shares in the capital, listed on Euronext Growth with ISIN code FR0010425595.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
-
News

Monthly information on share capital and company voting rights

Rhea-AI Summary
Cellectis announces voting rights for February 2024 with a total of 77,686,895 voting rights and 71,751,201 shares in the capital. The company's ISIN code is FR0010425595, listed on Euronext Growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
News

Monthly information on share capital and company voting rights

Rhea-AI Summary
Cellectis (CLLS) reports a total number of shares in the capital and voting rights as of January 31, 2024. The company's ISIN code is FR0010425595 and is listed on Euronext Growth. Media and investor relations contacts are provided for further information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
News

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has announced the drawdown of the second tranche of €15 million under a credit facility agreement with the European Investment Bank. The company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates. As a condition to the disbursement, the company issued warrants to the EIB, allowing them to subscribe for one ordinary share of the company at a specific price. The total number of shares issuable upon exercise of the warrants represents circa 2% of the company’s outstanding share capital at their issuance date. The tranche will mature in six years and accrue interest at a rate of 7% per annum. The company also has the option to drawdown a third tranche of up to €5 million, subject to certain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
none
-
News

Monthly information on share capital and company voting rights

Rhea-AI Summary
Cellectis (Euronext Growth: FR0010425595) reports a total number of shares in the capital as 71,751,201 and a total number of voting rights as 77,686,718 as of December 31, 2023. For further information, media contact is Patricia Sosa Navarro at +33 (0)7 76 77 46 93, media@cellectis.com. Investor Relations contacts are Arthur Stril at +1 (347) 809 5980, investors@cellectis.com and Ashley R. Robinson at +1 617 430 7577.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
News

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) held a shareholders general meeting at which resolutions 1 through 5 and 7 and 8 were adopted and resolution 6 was rejected. Shareholders supported a contemplated $140M additional investment by AstraZeneca, subject to clearance from the French Ministry of Economy. Mr. Marc Dunoyer and Dr. Tyrell Rivers were approved as directors of the Cellectis board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Monthly information on share capital and company voting rights

Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS) reports a total number of 71,751,201 shares in the capital and 77,686,109 voting rights as of November 30, 2023. For further information, please contact Media Chief of Staff Patricia Sosa Navarro at +33 (0)7 76 77 46 93 or media@cellectis.com, and Investor Relations Chief Business Officer Arthur Stril at +1 (347) 809 5980 or investors@cellectis.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
none

FAQ

What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?

The current stock price of Cellectis S.A. American Depositary Shares (CLLS) is $1.64 as of December 20, 2024.

What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?

The market cap of Cellectis S.A. American Depositary Shares (CLLS) is approximately 154.1M.

What does Cellectis S.A. specialize in?

Cellectis S.A. specializes in developing cancer immunotherapies using gene-edited T-cells, known as UCART.

What proprietary technologies does Cellectis use?

Cellectis uses its proprietary TALEN® technology and PulseAgile electroporation system for gene editing.

What are UCART cells?

UCART cells are allogeneic Chimeric Antigen Receptor T-cells developed to target and eradicate cancer cells.

What recent advancements has Cellectis made?

Cellectis has introduced a novel method for circularizing non-viral single-strand DNA templates to enhance gene editing outcomes in HSPCs.

Which companies has Cellectis partnered with?

Cellectis has partnership agreements with companies like AstraZeneca, expanding its pipeline of allogeneic CAR T-cell therapies.

On which stock markets is Cellectis listed?

Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets.

What are HSPCs?

HSPCs are hematopoietic stem and progenitor cells, which Cellectis gene-edits for various therapeutic applications.

How long has Cellectis been in the gene editing field?

Cellectis has over 18 years of expertise in the gene editing field.

Where can I find more information about Cellectis?

More information about Cellectis can be found on their website at www.cellectis.com.

How does Cellectis contribute to immuno-oncology?

Cellectis develops innovative immuno-oncology therapies by harnessing the power of gene-edited T-cells to fight cancer.

Stock CLLS logo
Cellectis S.A. American Depositary Shares

Nasdaq:CLLS

CLLS Rankings

#4087 Ranked by Market Cap
N/A Ranked by Dividends

CLLS Stock Data

154.14M
93.36M
3.87%
16.65%
0.14%
Biotechnology
Healthcare
Link
United States of America
Paris